Cargando…

Effects of burosumab on osteocalcin and bone mineral density in patient with 15-year history of nonremission tumor-induced osteomalacia initially treated with conventional therapy: Case report

Excess fibroblast growth factor 23 (FGF23) causes hypophosphatemic osteomalacia, which is associated with impaired bone matrix mineralization. Tumor-induced osteomalacia (TIO) is a rare paraneoplastic syndrome caused by over-secretion of FGF23 from a tumor. Burosumab, a fully human monoclonal antibo...

Descripción completa

Detalles Bibliográficos
Autores principales:	Miyaoka, Daichi, Imanishi, Yasuo, Yano, Masahiro, Toi, Norikazu, Nagata, Yuki, Kurajoh, Masafumi, Yamada, Shinsuke, Morioka, Tomoaki, Emoto, Masanori
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2020
Materias:	Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7701316/ https://www.ncbi.nlm.nih.gov/pubmed/33294501 http://dx.doi.org/10.1016/j.bonr.2020.100736

Ejemplares similares

Improvement of glycemic control by treatment for insomnia with suvorexant in type 2 diabetes mellitus
por: Toi, Norikazu, et al.
Publicado: (2018)

Parathyroid Hormone Regulates Circulating Levels of Sclerostin and FGF23 in a Primary Hyperparathyroidism Model
por: Nagata, Yuki, et al.
Publicado: (2022)

Nonremission and Recurrent Tumor‐Induced Osteomalacia: A Retrospective Study
por: Li, Xiang, et al.
Publicado: (2019)

Burosumab for the Treatment of Tumor‐Induced Osteomalacia
por: Jan de Beur, Suzanne M, et al.
Publicado: (2021)

Undercarboxylated osteocalcin does not correlate with insulin resistance as assessed by euglycemic hyperinsulinemic clamp technique in patients with type 2 diabetes mellitus
por: Mori, Katsuhito, et al.
Publicado: (2012)

Retroperitoneal Bronchogenic Cyst Adjacent to Adrenocortical Adenoma
por: Toi, Norikazu, et al.
Publicado: (2022)

Inverse association of plasma leptin with cortical thickness at distal radius determined with a quantitative ultrasound device in patients with type 2 diabetes mellitus
por: Kurajoh, Masafumi, et al.
Publicado: (2019)

Interim Analysis of a Phase 2 Open‐Label Trial Assessing Burosumab Efficacy and Safety in Patients With Tumor‐Induced Osteomalacia
por: Imanishi, Yasuo, et al.
Publicado: (2020)

Long-term use of burosumab for the treatment of tumor-induced osteomalacia
por: Crotti, C., et al.
Publicado: (2022)

Positive association of plasma leptin with sleep quality in obese type 2 diabetes patients
por: Hirota, Tomoe, et al.
Publicado: (2018)

Reply to: Burosumab for Tumor‐Induced Osteomalacia: not Enough of a Good Thing
por: Jan de Beur, Suzanne M., et al.
Publicado: (2021)

Tumour-induced osteomalacia: 18 months of 2-weekly burosumab treatment
por: Aliberti, L, et al.
Publicado: (2023)

Association of plasma xanthine oxidoreductase activity with vascular endothelial function independent of serum uric acid level: MedCity21 health examination registry
por: Kurajoh, Masafumi, et al.
Publicado: (2023)

Thyroid blood flow in inferior thyroid artery as predictor for increase in levothyroxine dosage during pregnancy in women with Hashimoto's thyroiditis - a retrospective study
por: Kurajoh, Masafumi, et al.
Publicado: (2019)

Uric acid shown to contribute to increased oxidative stress level independent of xanthine oxidoreductase activity in MedCity21 health examination registry
por: Kurajoh, Masafumi, et al.
Publicado: (2021)

Novel use of burosumab in refractory iron-induced FGF23-mediated hypophosphataemic osteomalacia
por: Amarnani, Raj, et al.
Publicado: (2020)

OR13-1 Burosumab Improves the Biochemical, Skeletal, and Clinical Symptoms of Tumor-Induced Osteomalacia Syndrome
por: Jan De Beur, Suzanne, et al.
Publicado: (2019)

OR29-06 Burosumab Improves Biochemical, Skeletal, and Clinical Features of Tumor-Induced Osteomalacia Syndrome
por: Carpenter, Thomas O, et al.
Publicado: (2020)

Favorable Effects of Burosumab on Fibroblast Growth Factor 23-Related Osteomalacia: A Case Report
por: Oe, Yuki, et al.
Publicado: (2021)

Favorable effects of burosumab on tumor-induced osteomalacia caused by an undetectable tumor: A case report
por: Oe, Yuki, et al.
Publicado: (2021)

Inflammation Related to Association of Low Uric Acid and Progression to Severe Disease in Patients Hospitalized for Non-Severe Coronavirus Disease 2019
por: Kurajoh, Masafumi, et al.
Publicado: (2023)

Insulin Resistance Associated with Plasma Xanthine Oxidoreductase Activity Independent of Visceral Adiposity and Adiponectin Level: MedCity21 Health Examination Registry
por: Kurajoh, Masafumi, et al.
Publicado: (2019)

Possible role of insulin resistance in activation of plasma xanthine oxidoreductase in health check-up examinees
por: Kurajoh, Masafumi, et al.
Publicado: (2022)

Significance of urinary C-megalin excretion in vitamin D metabolism in pre-dialysis CKD patients
por: Toi, Norikazu, et al.
Publicado: (2019)

Nutritional Status Association With Sarcopenia in Patients Undergoing Maintenance Hemodialysis Assessed by Nutritional Risk Index
por: Kurajoh, Masafumi, et al.
Publicado: (2022)

Glycated hemoglobin level on admission associated with progression to severe disease in hospitalized patients with non‐severe coronavirus disease 2019
por: Numaguchi, Ryutaro, et al.
Publicado: (2022)

Plasma soluble leptin receptor levels are associated with pancreatic β‐cell dysfunction in patients with type 2 diabetes
por: Morioka, Tomoaki, et al.
Publicado: (2017)

Burosumab Improved Histomorphometric Measures of Osteomalacia in Adults with X‐Linked Hypophosphatemia: A Phase 3, Single‐Arm, International Trial
por: Insogna, Karl L, et al.
Publicado: (2019)

Self-Administration of Burosumab in Children and Adults with X-Linked Hypophosphataemia in Two Open-Label, Single-Arm Clinical Studies
por: Kubota, Takuo, et al.
Publicado: (2023)

Reduced Risk of Progression from Non-Severe to Severe COVID-19 in Hospitalized Dialysis Patients by Full COVID-19 Vaccination
por: Ichii, Mitsuru, et al.
Publicado: (2022)

Plasma omentin levels are inversely associated with atherosclerosis in type 2 diabetes patients with increased plasma adiponectin levels: a cross-sectional study
por: Nishimura, Masami, et al.
Publicado: (2019)

Effects of fetuin-A-containing calciprotein particles on posttranslational modifications of fetuin-A in HepG2 cells
por: Uedono, Hideki, et al.
Publicado: (2021)

Burosumab for X-linked hypophosphataemia
Publicado: (2021)

Osteocalcin promotes bone mineralization but is not a hormone
por: Manolagas, Stavros C.
Publicado: (2020)

Thyroid heterogeneity, as indicated by the CV of ultrasonographic intensities, correlates with anti-thyroid peroxidase antibodies in euthyroid Hashimoto’s thyroiditis
por: Wakita, Yosuke, et al.
Publicado: (2013)

OR13-1 Long-Term Burosumab Therapy Provides Sustained Benefit in Patients with Tumor-Induced Osteomalacia: End of Study Findings From the Pivotal Phase 2 Study
por: Carpenter, Thomas, et al.
Publicado: (2022)

Is Stiffness Parameter β Useful for the Evaluation of Atherosclerosis?~ Its Clinical Implications, Limitations, and Future Perspectives ~
por: Morioka, Tomoaki, et al.
Publicado: (2021)

Direct Inhibitory Effects of Pioglitazone on Hepatic Fetuin-A Expression
por: Ochi, Akinobu, et al.
Publicado: (2014)

Development and Validation of a Nonremission Risk Prediction Model in  First-Episode Psychosis: An Analysis of 2 Longitudinal Studies
por: Leighton, Samuel P, et al.
Publicado: (2021)

Focal points of preanesthesia evaluations for electroconvulsive therapy in patients with depression: a retrospective analysis of clinical characteristics in nonremission
por: Zou, Lei, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_ggmivad48ina42t9krj38jj246